N-terminal telopeptide

NTx Appoints Steven Evans as Chief Scientific Officer

Retrieved on: 
Tuesday, February 27, 2024
Other Manufacturing, Technology, Research, Other Technology, Manufacturing, Other Health, Health, Other Science, Science, Pharmacology, Pfizer, Senior, Multimedia, GSK, Strategic planning, Drug development, Growth, Drug discovery, N-terminal telopeptide, RNA, Knowledge, CSO, Management

Nature’s Toolbox (NTx) a life sciences company building next generation platforms to manufacture RNA and protein, today announced the appointment of Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.

Key Points: 
  • Nature’s Toolbox (NTx) a life sciences company building next generation platforms to manufacture RNA and protein, today announced the appointment of Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.
  • View the full release here: https://www.businesswire.com/news/home/20240227674119/en/
    NTx has appointed Steven Evans, Ph.D. as Chief Scientific Officer and Senior Vice President of R&D.
  • At NTx, Steven will leverage his extensive skills in executive leadership, strategic planning, and cross-collaboration to drive the company’s R&D initiatives to new heights.
  • He has built an outstanding team of scientists and positioned the company for accelerated growth,” said Jamie Coffin, CEO of NTx.

NTx Raises $47.5M in Series B Funding to Advance Next Generation Biomanufacturing

Retrieved on: 
Thursday, November 16, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Sutro Biopharma, Protein, History, Vaccine, Venture round, Messenger, Therapy, Acceleration, N-terminal telopeptide, Drive, RNA, Nature

Nature's Toolbox, Inc. (NTx) , a life sciences company building next generation platforms to manufacture RNA and protein, announced today that it has raised $47.5M in Series B financing.

Key Points: 
  • Nature's Toolbox, Inc. (NTx) , a life sciences company building next generation platforms to manufacture RNA and protein, announced today that it has raised $47.5M in Series B financing.
  • Led by RA Capital Management, the investment will fuel the advancement of the company’s biomanufacturing platforms, NTxscribe® and NTxpress®.
  • This was also the largest Series B round raised by a New Mexico life sciences company in recent history," said Jamie Coffin, Ph.D., CEO of NTx.
  • The Series B funding will accelerate NTx’s development of the NTxscribe and NTxpress platforms into commercially available solutions including the manufacturing of biomaterials for producing mRNA and proteins.

Nature’s Toolbox Appoints Marcel Roche as Chief Financial Officer

Retrieved on: 
Tuesday, October 3, 2023
Research, Finance, Professional Services, Other Health, Biotechnology, General Health, Health, Science, Other Science, Other Professional Services, DNA, Growth, CFO, IPO, Helmy Eltoukhy, Multimedia, ERP, RNA, N-terminal telopeptide, Management

Nature’s Toolbox, Inc. (NTx) , a life sciences company facilitating innovative RNA and protein research and manufacturing, today announced the expansion of its leadership team with the appointment of Marcel Roche as Chief Financial Officer.

Key Points: 
  • Nature’s Toolbox, Inc. (NTx) , a life sciences company facilitating innovative RNA and protein research and manufacturing, today announced the expansion of its leadership team with the appointment of Marcel Roche as Chief Financial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231003392095/en/
    NTx has appointed Marcel Roche as Chief Financial Officer to steer financial strategies and drive growth.
  • "I am thrilled to be joining a company that delivers a trifecta of seasoned leadership, highly differentiated technology, and multi-billion-dollar addressable markets,” said Marcel Roche.
  • With a proven track record of financial acumen and strategic thinking, Marcel will play a pivotal role in steering our financial strategies and driving growth," said Jamie Coffin, Ph.D., CEO of NTx.

NTx Awarded BARDA DRIVe Vaccines on Demand Contract to Demonstrate a Novel RNA Vaccine Production Platform

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Vaccine, Biomedical Advanced Research and Development Authority, Therapy, U.S. Department of Commerce Office of Security, Human services, Office of Inspector General, U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, Infection, Houston Methodist Hospital, RNA, Messenger, Administration, Development, Professor, N-terminal telopeptide, BARDA, Nature

NTx, in collaboration with Houston Methodist Hospital, will demonstrate the potential of its NTxscribe platform to meet the needs for a scalable, rapidly deployable RNA manufacturing capability to support global vaccine preparedness and response.

Key Points: 
  • NTx, in collaboration with Houston Methodist Hospital, will demonstrate the potential of its NTxscribe platform to meet the needs for a scalable, rapidly deployable RNA manufacturing capability to support global vaccine preparedness and response.
  • The NTxscribe platform is a cell-free, true continuous flow manufacturing system that delivers scalable RNA (including mRNA and self-amplifying RNA) materials in a tabletop footprint.
  • This enzymatic process is designed to provide a low cost and rapidly deployable, vertically integrated manufacturing system.
  • Through this program, the system is being evaluated for its express development of RNA vaccines and therapeutics for infectious diseases, as well as its capability for distributed bio-manufacturing.

NTx Expands Commercial and Operational Teams to Accelerate Growth

Retrieved on: 
Thursday, April 27, 2023
Technology, Manufacturing, Health, General Health, Other Natural Resources, Other Science, Other Technology, Natural Resources, Research, Other Manufacturing, Science, REI, Business development, Senior, Marketing, Multimedia, RNA, CCO, The Cooper Companies, N-terminal telopeptide, Engineering, Growth, Management, Nature

She delivered double-digit growth every quarter for over three years achieving more than 300% growth in the testing footprint in women’s health and oncology.

Key Points: 
  • She delivered double-digit growth every quarter for over three years achieving more than 300% growth in the testing footprint in women’s health and oncology.
  • Earlier in her career, she held leadership roles at Dell Healthcare and Life Sciences, and IBM Healthcare and Life Sciences.
  • During his time there, he was able to optimize resources and polices to realize $2M cost avoidance annually in technical expenses.
  • For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com .

NTx Welcomes Accomplished Healthcare Industry Executive Dr. James Coffin as New CEO

Retrieved on: 
Wednesday, March 8, 2023
Managed Care, Research, Other Health, General Health, Pharmaceutical, Technology, Other Manufacturing, Science, Biotechnology, Other Technology, Health, Other Science, Manufacturing, RNA, Nature, CSO, Multimedia, Therapy, Dell, Pharmaceutical industry, Management, N-terminal telopeptide

Dr. Coffin has over 20 years of leadership experience within the healthcare and life sciences sector.

Key Points: 
  • Dr. Coffin has over 20 years of leadership experience within the healthcare and life sciences sector.
  • View the full release here: https://www.businesswire.com/news/home/20230308005163/en/
    NTx has appointed accomplished healthcare industry executive Dr. James Coffin as its new CEO.
  • (Photo: Business Wire)
    Earlier in his career, Dr. Coffin led the global, multi-billion-dollar healthcare and life sciences businesses at both Dell and IBM Healthcare.
  • “NTx’s novel technology has the potential to transform the way modern therapeutics are developed and accessed around the world,” said Dr. Jamie Coffin, CEO of NTx.

Nature’s Toolbox Names Yesim Roth as Chief Financial Officer

Retrieved on: 
Thursday, September 1, 2022
Other Manufacturing, Technology, Research, Other Technology, Manufacturing, Other Natural Resources, Other Science, Science, Natural Resources, VP, CEO, RNA, Technology, Computer science, Natural capital, Government, Time, Citibank, Brandeis University, IPO, International economics, Türk Telekom, Multimedia, N-terminal telopeptide, CFO, Smith College, Therapy, Druid, Growth, Industry, Management, Nature, Economics

Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that it has appointed Yesim Roth as Chief Financial Officer.

Key Points: 
  • Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that it has appointed Yesim Roth as Chief Financial Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220901005293/en/
    NTx has appointed Yesim Roth as Chief Financial Officer.
  • In this strategic role on the NTx executive team, Roth will lead financial systems improvements and contribute to organizational strategy.
  • NTx has developed a truly novel platform that can transform the way life-saving therapeutics are manufactured, said Yesim Roth.

Nature’s Toolbox Hires Mark Brancieri as Head of Manufacturing

Retrieved on: 
Wednesday, August 3, 2022
Other Science, Science, Bristol Myers Squibb, Good manufacturing practice, GSK, Process, N-terminal telopeptide, RNA, Engineering, Associate, Patient, SaRNA, Â, Biotechnology, CGMP, Process engineering, Natural computing, Technology, Druid, Solution, Therapy, Head, CEO, RNA transfection, Fine chemical, Nature, GlaxoSmithKline

Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that it has hired Mark Brancieri as Head of Manufacturing.

Key Points: 
  • Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that it has hired Mark Brancieri as Head of Manufacturing.
  • Prior to joining NTx, Brancieri served as the Process Engineering Director at global healthcare company, GlaxoSmithKline (GSK).
  • With the help of the manufacturing initiatives that Brancieri will lead, the NTx platform technologies will rapidly advance medical innovation to benefit patients.
  • Nature's Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico.

Nature’s Toolbox, Inc. to Present at the 2022 NIIMBL National Meeting

Retrieved on: 
Tuesday, July 19, 2022
Health, Technology, Other Technology, Other Science, General Health, Research, Science, N-terminal telopeptide, CEO, RNA, RNA transfection, National Institute, National meetings of the Workers' Party of Korea, Therapy, Druid, SaRNA, Industry, Partnership, Doctor of Philosophy, Next Generation, Fine chemical, Vaccine, Nature, D.C

NIIMBL is a public-private partnership with the mission to accelerate biopharmaceutical innovation and support the development of standards that enable more efficient and rapid manufacturing capabilities.

Key Points: 
  • NIIMBL is a public-private partnership with the mission to accelerate biopharmaceutical innovation and support the development of standards that enable more efficient and rapid manufacturing capabilities.
  • NIIMBL also educates and trains a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
  • The National Meeting is open to members and federal stakeholders only and promises three days of engaging content and robust discussions led by industry experts and thought leaders across the biopharmaceutical ecosystem.
  • Nature's Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico.

Nature’s Toolbox, Inc. to Participate in the 2022 BIO International Convention

Retrieved on: 
Thursday, June 9, 2022
Other Manufacturing, Research, Genetics, Manufacturing, Other Natural Resources, Biotechnology, Health, Natural Resources, Science, Other Science, Congress, Association, Research, San Diego Convention Center, BIO, CEO, RNA, Druid, Organization, Therapy, Private law, Vaccine, RNA transfection, N-terminal telopeptide, Natural computing, COVID-19, Public policy, Industry, Biotechnology Innovation Organization, SaRNA, Fine chemical, Pharmaceutical industry, Nature

Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that several of its executives will attend the Biotechnology Innovation Organization (BIO) International Convention taking place at the San Diego Convention Center from Monday, June 13 Thursday, June 16, 2022.

Key Points: 
  • Nature's Toolbox, Inc. (NTx) , a life sciences company enabling novel RNA product development, today announced that several of its executives will attend the Biotechnology Innovation Organization (BIO) International Convention taking place at the San Diego Convention Center from Monday, June 13 Thursday, June 16, 2022.
  • Its cell-free, continuous-flow process mitigates the typical development challenges by producing extended length material and helps accelerate pre-clinical candidates towards regulatory filings and clinical studies.
  • BIO is the worlds largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries.
  • Nature's Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico.